# US 2002/0058839 A1 · Methods and compositions for modulating alpha adrenergic receptor activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058839 A1
- Document ID: US20020058839A1
- Status: Published application
- Kind: A1
- Application number: 09/778,975
- Filed: 2001-02-05
- Published: 2002-05-16
- Earliest claimed: 2000-04-13
- Assignees: Allergan Sales, Inc.
- Inventors: Ken Chow; Daniel W. Gil; Wenkui Fang; Michael E. Garst; Larry A. Wheeler
- Web page: https://patentgrep.com/patent/US20020058839A1

## CPC

- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 335/12: the carbon skeleton containing six-membered aromatic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Methods and compositions for the treatment of pain. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.

## Claims

### Claim 1

A composition comprising a compound represented by the formula:
86
wherein R1 and R5 are independently selected from the group consisting of Cl, F, I, Br, C1-3 alkyl, C1-3 alkoxy, trifluoromethyl, hydroxyl or H, R2 and R4 are independently selected from the group consisting of Cl, F, I, Br, C1-3 alkyl, C1-3 alkoxy, hydroxyl, trifluoromethyl or H, and R3 is selected from the group consisting of F or H; and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds,
and a pharmaceutically acceptable excipient.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the compound is not represented by the formula:
87
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the compound is not represented by the formula:
88
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the compound is not represented by the formula
89
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 5 (depends on 1)

The composition of claim 1 wherein said composition comprises a pharmaceutically acceptable excipient for therapeutic delivery of said compound.

### Claim 6 (depends on 5)

The composition of claim 5 wherein said compound is not represented by the formula:
90
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 7 (depends on 5)

The composition of claim 5 wherein said compound is not represented by the formula:
91
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 8 (depends on 7)

The composition of claim 7 wherein the compound is not represented by
92
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 9

A method of treating pain in a mammal in need thereof comprising the step: administering to said patient a therapeutically effective dose of a composition comprising a compound represented by having the formula:
93
wherein R1 and R5 are independently selected from the group consisting of Cl, F, I, Br, C1-3 alkyl, C1-3 alkoxy, trifluoromethyl, hydroxyl or H, R2 and R4 are independently selected from the group consisting of Cl, F, I, Br, C1-3 alkyl, C1-3 alkoxy, hydroxyl, trifluoromethyl or H, and R3 is selected from the group consisting of F or H; and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 10 (depends on 9)

The method of claim 9 wherein said compound is not represented by the formula
94
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 11 (depends on 10)

The method of claim 10 wherein said compound is administered orally.

### Claim 12 (depends on 9)

The method of claim 9 wherein said compound is not represented by the formula
95
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 13 (depends on 9)

The method of claim 9 wherein said compound is administered orally.

### Claim 14 (depends on 12)

The method of claim 12 wherein said compound is not represented by the formula
96
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 15

A compound represented by the formula:
97
wherein R1, R2, R3, R4 and R5 are each independently selected from the group consisting of Cl, F, Br or H with the proviso that at least one of R2 and R4 are Cl, F, or Br and that at least three of R1, R2, R3, R4, and R5 are H; and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 16 (depends on 15)

A compound of claim 15 not represented by the formula
98
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 17 (depends on 15)

A compound of claim 15 not represented by the formula
99
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.

### Claim 18 (depends on 17)

A compound of claim 17 not represented by the formula
100
and alkyl esters thereof, and pharmaceutically acceptable salts of these compounds.
